Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AJZ Engineering to re-equip Russian cancer centre:

This article was originally published in Clinica

Executive Summary

German company AJZ Engineering has been contracted to modernise and equip the "Blochin" Oncology Research Centre at the Russian Academy of Medical Sciences in Moscow. The contract is worth E60 million ($50 million) and involves re-equipping the surgery centre, the bone marrow transplant centre and the central sterilisation facility, and modernising parts of the centre's radiation therapy and laboratory diagnostic units. The project is expected to take two years. Jena-based AJZ Engineering will include a number of companies from eastern Germany in the project, mostly from Thuringia. The company co-operated with Siemens Medical Solutions to modernise the radiation therapy and imaging diagnostics units. AJZ Engineering is a joint venture of Analytik Jena and Carl Zeiss Jena.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT066522

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel